2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Precipio reported second-quarter 2026 revenue of $7.0 million, up from $6.7 million in the first quarter and 22% above the $5.7 million in the year-earlier quarter. Adjusted EBITDA, a non-GAAP measure, was $0.4 million, compared with a $(0.2) million loss in the first quarter, but the company's GAAP net result was a loss of $(0.2) million versus net income of $0.1 million a year earlier.
Q2 2026 revenue was $7.0 million, including $6.1 million in pathology revenue and $0.9 million in product revenue.
Adjusted EBITDA was $0.4 million in Q2 2026, versus $(0.2) million in Q1 2026.
GAAP net loss was $(0.2) million in Q2 2026, compared with net income of $0.1 million in Q2 2025.
Cash was over $3 million at quarter end, versus $1.1 million in Q2 2025, with $0.7 million generated from operations in the quarter.
MediaCo reported second-quarter 2026 net revenues of $34.0 million, up 9% from a year earlier, driven by digital advertising. Net loss widened 17% to $8.6 million, and Adjusted EBITDA fell 38% to $0.9 million, so higher revenue did not translate into better profitability for shareholders.
Q2 2026 net revenues were $34.0 million ($33,969 thousand), up 9% from $31.2 million in Q2 2025.
Q2 2026 net loss was $8.6 million, compared with $7.4 million a year earlier, citing higher operating and corporate expenses and interest costs.
Q2 2026 Adjusted EBITDA was $0.9 million, down from $1.5 million in Q2 2025.
First-half 2026 net revenues were $65.4 million, up 10%, while the first-half net loss was $18.0 million versus $16.0 million.
Wheels Up Experience said its Chief Sales Officer, Mark Briffa, will leave the role and remain with the company to transition his duties through September 1, 2026. David Godsman, the Chief Digital Officer, will lead the global sales organization on an interim basis, and a settlement agreement dated August 12, 2026 sets out Briffa's separation payments and equity treatment.
Briffa agreed on August 10, 2026 to depart as Chief Sales Officer, with his transition running through September 1, 2026.
David Godsman takes interim leadership of global sales in addition to his Chief Digital Officer role.
Settlement agreement with subsidiary Air Partner Limited provides continued salary through December 31, 2026 and severance lump sums totaling £378,354.82, less deductions.
A full-year 2026 bonus is payable in 2027 subject to plan metrics; RSUs and PSUs vest on original schedules through September 1, 2027, and all other equity awards were forfeited.
Retractable Technologies reported second-quarter 2026 net sales of $7.2 million, down from $10.4 million a year earlier, with an operating loss of $5.1 million in both periods. The company attributed the sales decline mainly to the timing of EasyPoint needle orders and to unusually high flu season unit sales in the second quarter of 2025. Second-quarter net income of $2.8 million was driven by a $6.4 million gain on the sale of equity securities, while the first half shows a net loss of $1.4 million and a wider operating loss of $11.3 million.
Q2 2026 net sales were $7.2 million versus $10.4 million in Q2 2025; operating loss was $5.1 million in both periods.
First-half 2026 net sales were $14.4 million versus $18.7 million; operating loss widened to $11.3 million from $9.8 million.
Q2 2026 net income of $2.8 million included a $6.4 million realized gain on sale of equity; first-half net loss was $1.4 million.
A reduction in force in April 2026 is expected to produce cost savings in future periods.
Canton Strategic Holdings reported its first operating revenue for the quarter ended June 30, 2026, $1,495,859, compared with $0 a year earlier. The company also posted a net loss of $19,254,826, or $(0.08) per share, which includes a $23,735,950 unrealized loss on its Canton Coin holdings, so the larger loss and the revenue gain both bear on shareholder returns.
Total revenue was $1,495,859 for the three months ended June 30, 2026, versus $0 in the same period of 2025; the filing says the LaaS offering drove about $1.3 million of it.
Net loss was $19,254,826, or $(0.08) per basic and diluted share from continuing operations, including a $23,735,950 unrealized loss on digital asset holdings.
Cash and cash equivalents were $37,241,568 as of June 30, 2026, up from $12,007,148 as of December 31, 2025.
The sale of Gravitas Life Sciences, Inc. closed on July 17, 2026, for an unsecured promissory note of $3,500,000 bearing 15% payment-in-kind interest, plus contingent milestone payments.
HeartBeam, Inc. signed an at-the-market equity offering sales agreement with Titan Partners Securities LLC, allowing it to sell up to $25,000,000 of common stock over time through the sales agent. Sales would be made under an existing shelf registration statement and a prospectus supplement dated August 14, 2026, and the sales agent would receive a commission of up to 3% of gross sales price, which could dilute existing shareholders.
Agreement dated August 14, 2026 with Titan Partners Securities LLC as sales agent
Up to $25,000,000 of common stock, par value $0.0001 per share, may be sold from time to time
Commission of up to 3% of gross sales price per share sold through the agent
Sales would be made under Form S-3 shelf Registration No. 333-293307 and a prospectus supplement dated August 14, 2026
Jacobs Solutions said its President, Strategy, Growth & Digital, Shannon Miller, transitioned from that role on August 10, 2026, and will serve as Special Advisor to the CEO until she leaves the company, no later than October 3, 2026. The filing gives no successor, financial effect, or reason for the change.
Shannon Miller's role as President, Strategy, Growth & Digital ended with a transition on August 10, 2026.
Miller will serve as Special Advisor to CEO Robert V. Pragada until her departure.
Her departure from the company is due no later than October 3, 2026.
The filing does not name a replacement or disclose compensation terms.
NYSE Regulation accepted Actinium's compliance plan on August 12, 2026, and granted a plan period through November 27, 2027, to regain compliance with NYSE American continued listing standards. The company's common stock will keep trading on NYSE American during the plan period, but the company remains out of compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.
NYSE American notified the company on May 27, 2026, that it was not in compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.
The company submitted its compliance plan on June 18, 2026, and NYSE Regulation accepted it in an August 12, 2026 letter.
The plan period runs through November 27, 2027, and the stock continues to trade under the symbol ATNM during this period.
If the company does not regain compliance or make progress consistent with the plan by the end of the period, NYSE Regulation may initiate delisting proceedings.
KinderCare Education, a wholly-owned subsidiary, entered into an Amended and Restated Fifth Amendment to its master lease covering 545 center sites with landlord KCP RE LLC, effective August 11, 2026. The amendment extends lease terms to between December 31, 2033 and December 31, 2042 for most sites, but raises the cap on annual rent escalations from 10% to 12.5%, which increases the potential cost of future rent adjustments.
Schedule 1 (13 sites) was transferred to affiliate KCP RE II LLC under a new master lease ending December 31, 2029, at the same annual rent.
Lease expirations for Schedules 2 through 6 range from December 31, 2033 to December 31, 2042, with one five-year extension option for Schedules 4 through 6.
The escalation percentage is the lesser of 12.5% (previously 10%) or the applicable index increase, with adjustment dates from August 1, 2030.
Carvana entered a $1.66 billion senior secured term loan B credit agreement on August 14, 2026, maturing in 2033. The company said the proceeds are expected to redeem or refinance its 2030 Secured Notes, with $1.0 billion redeemed on August 15, 2026 and the remainder on August 22, 2026.
Term loan B facility of $1.66 billion matures August 14, 2033, issued at 99.75% of principal.
Interest is Term SOFR plus 2.25% or base rate plus 1.25%, per the credit agreement.
Proceeds expected to redeem 2030 Secured Notes: $1.0 billion on August 15, 2026 and the remainder on August 22, 2026.
The credit agreement has no financial covenant and requires 50% excess cash flow prepayments starting fiscal 2028, subject to reductions.
Air T reported fiscal 2027 first-quarter results for the period ended June 30, 2026, with revenue up 63% to $115.5 million but an operating loss of $12.8 million compared with operating income of $0.8 million a year earlier. The company attributed the loss mainly to transaction and integration costs for Crestone's June 10 acquisition of Arena Aviation Capital and to depreciation from the fair-value step-up of the Rex aircraft fleet. Shareholders are seeing higher revenue alongside lower profitability in the quarter.
Q1 revenue was $115.5 million, up $44.6 million, or 63%, from the prior-year quarter.
Q1 operating loss was $12.8 million versus operating income of $0.8 million a year earlier; Adjusted EBITDA was $0.8 million, down 45% from $1.5 million.
Trailing twelve-month revenue was $371.7 million, up 25%, while the trailing twelve-month operating loss was $24.9 million.
Crestone acquired Arena Aviation Capital on June 10 for $33.9 million, including $21.7 million in cash and $12.2 million of contingent consideration; Blue Owl funded $10.0 million for preferred units representing 10.25% of the platform.
Pinnacle Acquisition Corp, a blank check company, closed its initial public offering of 20,000,000 units at $10.00 per unit on August 10, 2026, generating $200 million in gross proceeds that were placed in a trust account. In an amendment to its underwriting agreement, the underwriter's deferred discount of $0.30 per unit will not accrue or be payable on 2,250,000 units bought by two co-managing members of the sponsor or their affiliate, which caps the maximum deferred discount at $5,325,000 (or $6,225,000 if the over-allotment option is exercised in full).
IPO of 20,000,000 units at $10.00 per unit, closed August 10, 2026, for $200 million in gross proceeds
Each unit has one Class A ordinary share and one right to receive one-eighth of a share upon completing a business combination
Private placement of 225,000 units to the sponsor at $10.00 per unit, for $2.25 million in gross proceeds
Deferred discount of $0.30 per unit waived on 2,250,000 units bought by Steven K. Hudson and AVR Capital Holdings, LLC; maximum deferred discount is $5,325,000
Nakamoto reported second-quarter 2026 results on August 13, 2026, with total operating revenue of $35.9 million, an operating loss of $149.1 million, and a net loss of $133.0 million, or $6.65 per diluted share. The company said the losses were driven mainly by $105.2 million of non-cash goodwill impairment charges and $48.7 million of mark-to-market losses on digital assets. Shareholders face a large GAAP loss even though the company reported $7.3 million of adjusted operating income and reduced debt by about $45 million.
Total operating revenue was $35.9 million for the quarter ended June 30, 2026; the prior-year quarter shows no revenue figures in the filing.
Net loss was $133.0 million, or $6.65 per diluted share, compared with a net loss of $2.4 million in the second quarter of 2025.
Adjusted operating income, a non-GAAP measure, was $7.3 million, which the company said was its first positive adjusted operating income since becoming a Bitcoin operating company.
As of June 30, 2026, the company held 4,467 Bitcoin with an aggregate fair value of approximately $261.5 million and authorized a share repurchase program of up to $25 million.
On August 14, 2026, Target entered into a five-year, $4.0 billion unsecured revolving credit agreement that expires August 14, 2031, with two one-year extension options. On the same date, Target terminated its prior $3.0 billion five-year credit agreement and its $1.0 billion 364-day credit agreement, which were scheduled to expire in 2028 and October 2026. The filing says the other terms of the terminated agreements were substantially similar to the new facility, and it includes a leverage ratio covenant.
New $4.0 billion unsecured revolving credit facility expires August 14, 2031, with two one-year extension options.
Target may increase commitments by up to an additional $1.0 billion, subject to conditions.
Terminated a $3.0 billion facility dated October 18, 2021 (scheduled to expire October 18, 2028) and a $1.0 billion 364-day facility (scheduled to expire October 8, 2026).
Includes a leverage ratio financial covenant; obligations may be accelerated if an event of default is not cured or waived.
Thunder Bridge Capital Partners V, Ltd. closed its initial public offering of 30,015,000 units at $10.00 per unit on August 14, 2026, including 3,915,000 units from the full exercise of the underwriters' over-allotment option. The company is a special purpose acquisition company with no business combination yet, and all $300,150,000 of IPO and private placement proceeds was placed in a trust account, which shareholders can access only under the conditions set out in the filing.
30,015,000 units sold at $10.00 each, including 3,915,000 units from the full over-allotment exercise, for gross proceeds of $300,150,000
Private placement of 747,000 units to the Sponsor and Cantor at $10.00 per unit, for approximately $7,470,000
$300,150,000 placed in a trust account with Continental Stock Transfer & Trust Company; funds are released only after an initial business combination, a qualifying shareholder vote, or a failure to complete a business combination within 24
Four directors, David Burg, Mary Anne Gillespie, Stewart J. Paperin and Allerd D. Stikker, were appointed August 12, 2026; units began trading under TBCVU on August 13, 2026
Air T reported fiscal first-quarter 2027 revenue of $115.5 million, up 63% from a year earlier, with $55.9 million coming from its Rex regional airline acquisition completed on December 18, 2025. The company swung to an operating loss of $12.8 million from operating income of $0.8 million a year earlier, and net loss per share was $5.86 versus $0.61, so higher sales did not translate into profit for shareholders.
Revenue $115.5 million, up $44.6 million or 63%; Rex contributed $55.9 million
Operating loss $12.8 million versus operating income of $0.8 million in the prior-year quarter
Net loss per share $5.86 versus $0.61; loss before income taxes $15.0 million versus $0.8 million
Adjusted EBITDA (a non-GAAP measure) $0.8 million versus $1.5 million; Regional Airline segment cited fuel expense of $11.8 million as the primary driver of its operating loss
Maui Land & Pineapple reported results for the six months ended June 30, 2026, in Exhibit 99.1 to a Form 8-K. Total operating revenues fell to $7.1 million from $10.4 million a year earlier, while the net loss narrowed to $3.7 million from $9.6 million, mainly because the prior year included pension charges. Shareholders face lower revenue and a higher line of credit balance alongside the smaller loss.
Total operating revenues were $7.1 million for the six months ended June 30, 2026, versus $10.4 million a year earlier.
Net loss was $3.7 million, or $0.19 per share, versus $9.6 million, or $0.49 per share, a year earlier.
Land development and sales revenue was $0.5 million, down from $4.1 million; the company cited contracted sales, including a $10.0 million agreement with Harvest Church expected to close in 2027.
Cash and cash equivalents were $3.3 million at June 30, 2026, and the line of credit balance rose to $8.5 million from $4.0 million at December 31, 2025.
Hallador Energy entered into a Third Amendment to its Credit Agreement with Texas Capital Bank as administrative agent on August 11, 2026. The amendment changes how EBITDA is defined, allowing certain power purchase agreement exclusivity payments received in the quarter ended June 30, 2026 to be added back, up to $10 million in aggregate.
Amendment dated August 11, 2026, to the Credit Agreement originally dated March 5, 2026
Permits add-back to EBITDA of PPA exclusivity payments received in the quarter ended June 30, 2026, capped at $10,000,000
Texas Capital Bank serves as administrative agent; the full amendment is filed as Exhibit 10.1
AgEagle reported second quarter 2026 revenue of $2.7 million, nearly double the first quarter but down from $4.1 million in the second quarter of 2025. Cash and cash equivalents fell to $15.9 million at June 30, 2026, from $29.5 million at December 31, 2025, so the sequential rebound comes with lower year-over-year sales and a smaller cash balance.
Revenue of $2.7 million, compared with $1.4 million in Q1 2026 and $4.1 million in Q2 2025
Gross margin of 50.6%, up from 41.7% in Q1 2026 but below 56% in Q2 2025
Cash and cash equivalents of $15.9 million at June 30, 2026, down from $29.5 million at December 31, 2025
Company expects continued revenue progression in the second half of 2026 but gave no numeric guidance; nine eBee VISION systems are expected to ship in Q3 2026
Adagio Medical Holdings received a Nasdaq deficiency letter on August 13, 2026, saying it does not meet the minimum $2,500,000 stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company reported stockholders' equity of $(415,000) in its June 30, 2026 quarterly report, and the notice has no immediate effect on its listing. Shareholders should note the company must submit a compliance plan by September 28, 2026, and the company's filing cites going concern and financing risks.
Nasdaq notice received August 13, 2026 for stockholders' equity below $2,500,000 minimum
Reported stockholders' equity of $(415,000) in Form 10-Q for period ended June 30, 2026
Compliance plan due by September 28, 2026; Staff may grant up to 180 calendar days to regain compliance if plan is accepted
Company does not meet alternative standards of $35 million market value of listed securities or $500,000 net income
CXApp Inc. (Nasdaq: CXAI) filed a certificate of amendment to combine every 50 shares of its common stock into one share, effective 12:01 a.m. Eastern Time on August 18, 2026. The company says the primary purpose is to raise the per-share price to regain and maintain compliance with Nasdaq's $1.00 minimum bid price rule. The split does not change any stockholder's percentage ownership, except for fractional share treatment, and the warrants' exercise price and share count are adjusted to match.
Ratio: 1-for-50; approximately 116,870,315 shares outstanding before the split would become approximately 2,337,407 shares
Trading under the symbol CXAI continues on the Nasdaq Capital Market with a new CUSIP number, 23248B 307, starting August 18, 2026
Public Warrants (CXAIW): exercise price rises from $11.50 to $575.00, and each warrant becomes exercisable for 1/50th of a share
Stockholders stated in the Annual Meeting on June 16, 2026 approved the split at a ratio between 1-for-5 and 1-for-100; the Board chose 1-for-50
Traws Pharma reported its quarter ended June 30, 2026, with no revenue, compared with $2.7 million a year earlier, and a net loss of $3.0 million, or $0.16 per share, versus a $0.9 million loss, or $0.11 per share, in the same period of 2025. The company said its cash and equivalents, plus expected at-the-market equity proceeds, should fund operations into the first quarter of 2027, and that it may need additional financing after that.
Q2 2026 revenue was zero, down from $2.7 million in Q2 2025, which included a non-recurring deferred revenue recognition tied to a licensing termination.
Q2 2026 net loss was $3.0 million ($0.16 per share); six-month net loss was $10.2 million, compared with $20.6 million net income in the first half of 2025, which included a $26.7 million non-cash warrant gain.
Cash and cash equivalents were $5.0 million at June 30, 2026, up from $3.8 million at December 31, 2025, mainly from the April 2026 private placement and ATM sales.
Shareholders approved the Series B and Series C financing tranches on July 8, 2026; the company says access remains subject to milestones and investor participation, and the FDA clinical hold on tivoxavir marboxil is still pending resolutio
Optimum Communications received a New York Stock Exchange notice on August 13, 2026, because the average closing price of its Class A common stock fell below $1.00 over 30 consecutive trading days. The notice has no immediate effect on the stock's listing, but if the company does not regain compliance within six months, the NYSE will begin procedures to suspend and delist the shares.
NYSE notice received August 13, 2026, under Section 802.01C of the NYSE Listed Company Manual
Company has six months from receipt to regain compliance by meeting the $1.00 minimum closing and 30-day average price test
Company intends to monitor the share price through February 13, 2027; board will consider other options if compliance appears unlikely
Curing the price condition through an action requiring stockholder approval would need approval no later than the next annual meeting
Heron Therapeutics amended its Tax Benefit Preservation Plan, a shareholder rights arrangement generally designed to protect the company's tax attributes, extending its Final Expiration Date from August 14, 2026 to August 14, 2029. The filing does not describe a change in the company's financial results or operations, but the extension changes the length of the plan that shareholder rights are tied to.
Amendment No. 1 was entered into on August 13, 2026, with Computershare Trust Company, N.A. as rights agent.
The Final Expiration Date of the original plan, dated August 14, 2025, moves from August 14, 2026 to August 14, 2029.
The amendment is filed as Exhibit 4.1 and is incorporated into Item 3.03 as a material modification to rights of security holders.
Exzeo Group's Board of Directors authorized a program to buy back up to $25 million of the company's common shares, subject to market conditions, as announced August 14, 2026. The program runs for one year, does not require the company to buy a set number of shares, and can be canceled or suspended at any time.
Authorized repurchase amount: up to $25 million of common shares
Program term: one year; no obligation to buy a specific number of shares
Purchases may be made in open market, block, or privately negotiated transactions, including under a Rule 10b5-1 plan
Announced August 14, 2026 in Exhibit 99.1 press release
Solana Company reported a second-quarter 2026 net loss of $30.3 million, or $0.38 per share, compared with a net loss of $9.8 million in the prior-year quarter. Revenue rose to $2.5 million, mainly from staking on its SOL holdings, but operating expenses reached $35.1 million, including $6.8 million of severance tied to the divestiture of its legacy PoNS medical device business.
Q2 2026 revenue was $2.5 million, almost all staking revenue, versus $43 thousand a year earlier
Q2 2026 net loss was $30.3 million, or $0.38 per share, versus $9.8 million in the prior-year quarter
General and administrative expenses were $11.1 million, including $6.8 million of severance tied to the PoNS divestiture
Total assets were $176.1 million at June 30, 2026, down from $303.9 million at December 31, 2025, and cash was $3.6 million
Seritage Growth Properties reported second-quarter 2026 results with a net loss attributable to common shareholders of $7.4 million, or $0.13 per share, compared with $29.7 million, or $0.53 per share, a year earlier. Revenue fell sharply to $1.9 million from $4.7 million, while the company repaid its $50.0 million term loan using new loans and cash on hand, and said it continues to explore a strategic transaction.
Q2 2026 net loss attributable to common shareholders was $7.4 million ($0.13 per share), versus $29.7 million ($0.53 per share) in Q2 2025.
Q2 2026 total revenue was $1.9 million, versus $4.7 million in Q2 2025.
Six-month net loss was $38.9 million ($0.69 per share), including a $15.2 million impairment on one consolidated property.
On July 24, 2026, the company closed a $15.0 million term loan and $25.0 million revolver, drew $15.0 million, and repaid the $50.0 million term loan balance.
Delek Logistics Partners closed its underwritten public offering of 4,600,000 common units at $50.00 per unit, including 600,000 units from the underwriters' full exercise of their option. The partnership intends to use the approximately $220.8 million in gross proceeds after underwriting fees to repay revolving credit borrowings and for general partnership purposes. Delek Holdings bought none of the units, so its ownership of the partnership fell from 63.0% to approximately 58.0%.
Offering of 4,600,000 common units at $50.00 per unit closed, including 600,000 units from full exercise of the underwriters' option.
Approximately $220.8 million in proceeds, after underwriting fees, to repay revolving credit borrowings and for general partnership purposes.
Delek Holdings' ownership of common units declined from 63.0% before the offering to approximately 58.0% after closing.
Truist Securities, Mizuho, and Raymond James & Associates acted as joint book-running managers.
Cerenome reported second quarter 2026 results on August 14, 2026. Grant revenue fell to $0.4 million from $1.4 million a year earlier, the operating loss widened to $9.1 million from $1.5 million, and the company posted a net loss of $9.0 million, or $1.31 per basic share, compared with net income of $5.2 million in the prior-year quarter, which included a $6.5 million gain from a change in fair value of derivative instruments. Cash and investments totaled $8.6 million at June 30, 2026, and the company affirmed its 2026 milestones and outlook without changes.
Operating loss was $9.1 million in Q2 2026 versus $1.5 million in Q2 2025, which the company attributes mainly to expansion of CNSide commercial operations and funding of the REYOBIQ Phase 2 trial.
Net loss was $9.0 million, or $1.31 per basic share, versus net income of $5.2 million, or $0.62 per basic share, in Q2 2025.
Cash, cash equivalents and investments were $8.6 million as of June 30, 2026.
The company affirmed its 2026 milestones, including ReSPECT-GBM data expected in Q1 2027.
Gaxos.ai agreed with holders of existing warrants to exercise 3,007,654 shares at a reduced price of $1.20 per share, down from original exercise prices of $2.33 to $3.32. In exchange, the company will issue new warrants for up to 6,015,308 shares at $0.95 per share, with a three-year term. Gross proceeds are expected to be about $3.6 million before placement agent fees and offering expenses, which would add cash for working capital but could increase the number of shares outstanding if the new warrants are exercised.
Existing warrants for 3,007,654 shares to be exercised at $1.20 per share, with gross proceeds of about $3.6 million expected before fees
New warrants for up to 6,015,308 shares at $0.95 per share, with a three-year term
H.C. Wainwright & Co. is placement agent, with a 7.0% cash fee and 1.0% management fee on exercise proceeds, plus warrants for 150,383 shares at $1.50
Closing expected on August 17, 2026; company to file a resale registration statement within 30 days of closing
U.S. Physical Therapy appointed Nchacha Etta as Executive Vice President and Chief Financial Officer, effective September 1, 2026, ending Jason Curtis's role as interim CFO. Etta's employment agreement sets a $625,000 base salary and equity grants of about $550,000 and $200,000, with severance and change-in-control benefits that shareholders may want to note.
Base salary of $625,000 per year, plus discretionary bonuses set by the Board or compensation committee
Initial restricted stock grant of about $550,000 vesting in equal quarterly installments over four years
Change-in-control benefit of $283,333; termination without cause or for good reason triggers two years of base pay plus bonus-related payments
Jason Curtis, SVP Finance and Accounting, stops serving as interim CFO and remains SVP
Smith-Midland reported second-quarter 2026 revenue of $23.4 million, down from $26.2 million a year earlier, and net income of $1.4 million, or $0.26 per diluted share, down from $4.2 million, or $0.79. The company attributed the decline mainly to a higher-margin special barrier rental project in the 2025 quarter that did not recur. Backlog was approximately $57.4 million as of August 1, 2026, up from $54 million a year earlier.
Revenue was $23.4 million versus $26.2 million; product sales were $11.2 million versus $13.4 million.
Gross margin was 23.2% versus 29.7%, mainly due to the special barrier rental project in Q2 2025 that did not recur.
Net income was $1.4 million, or $0.26 per diluted share, versus $4.2 million, or $0.79 per diluted share.
Backlog was approximately $57.4 million as of August 1, 2026, compared with $54 million one year earlier.
Enova subsidiary NetCredit LOC Receivables 2024 amended its credit facility, raising the revolving commitment from $200 million to $300 million, extending the revolving period to February 21, 2029, extending maturity to February 21, 2030, and lowering the borrowing rate from SOFR + 5.50% to SOFR + 5.00%. Separately, an indirect subsidiary priced $300,886,000 of 2026-A Notes backed by unsecured consumer installment loans, with closing expected on or about August 21, 2026; the notes are not guaranteed by Enova.
Revolving commitment increases from $200 million to $300 million, with the revolving period extended to February 21, 2029.
Borrowing rate decreases from SOFR + 5.50% to SOFR + 5.00%; maturity extended from February 21, 2028 to February 21, 2030.
2026-A Notes total $300,886,000: Class A $240,709,000 at 5.88%, Class B $44,341,000 at 7.68%, Class C $15,836,000 at 10.64%.
Notes are priced subject to market conditions, with anticipated closing on or about August 21, 2026; they are offered only to qualified institutional buyers and certain non-U.S. persons.
Enveric Biosciences reported a second-quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, and cash on hand of $8.3 million as of June 30, 2026. The company also gave an update on its lead drug candidate EB-003, including preclinical data and the start of genotoxicity studies ahead of a planned IND submission.
Net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, versus $2.5 million a year earlier.
Basic and diluted loss per share was $0.76, compared with $11.65 in the second quarter of 2025.
The company raised $5.0 million in gross offering proceeds and $1.5 million from warrant exercises in the quarter.
Genotoxicity studies for EB-003 were initiated, a step the filing describes as required for IND submission.
On August 12, 2026, Reed's received a notice from NYSE American that it is below the $2.0 million stockholders' equity requirement and is not eligible for an exemption. NYSE American accepted the company's compliance plan that day, with a deadline of November 29, 2027 to regain compliance, and the company will face periodic reviews and possible delisting proceedings if it falls short.
Company reported a stockholders' deficit of $(1.5) million, below the $2.0 million NYSE American minimum.
NYSE American accepted the compliance plan, submitted June 26, 2026, on August 12, 2026.
Company must regain compliance by November 29, 2027, or NYSE American will initiate delisting proceedings as appropriate.
Shares continue to trade as REED with a ".BC" (below compliance) designation.
Barfresh reported second quarter 2026 revenue of $4.7 million, up 190% year over year, driven by the Arp's Dairy acquisition. The company also reported a gross loss, a net loss of $1.9 million and an Adjusted EBITDA loss of $1.2 million, and it revised its full year 2026 guidance lower, citing slower production efficiency gains at its existing facility.
Q2 2026 revenue was $4.7 million, up from $1.6 million in Q2 2025, with a gross loss of $150,000 versus gross profit of $506,000 a year earlier.
Q2 2026 net loss was $1.9 million, compared with $880,000 in Q2 2025; Adjusted EBITDA loss was $1.2 million, compared with $600,000.
FY 2026 revenue guidance is $23 million to $26 million, or 62% to 83% growth; FY 2026 Adjusted EBITDA guidance is negative $1.0 million to $2.0 million.
The company expects Adjusted EBITDA of negative $0.5 million to breakeven in the second half of 2026.
VICI Properties L.P., the operating partnership of VICI Properties Inc., completed sales of $900 million of 5.400% notes due 2031 and $850 million of 5.750% notes due 2036 on August 14, 2026. It plans to use the proceeds to repay existing senior notes maturing in 2026, including $1.25 billion of 4.250% notes due December 2026 and $480.5 million of 4.500% notes due September 2026, which the filing says it expects to redeem on August 17, 2026.
$900 million of 5.400% notes due October 15, 2031, issued at 99.966% of par value
$850 million of 5.750% notes due October 15, 2036, issued at 98.375% of par value
Proceeds intended to repay $1.25 billion of 4.250% notes due December 2026 and $480.5 million of 4.500% notes due September 2026, with redemption expected August 17, 2026
The notes are unsecured, are not guaranteed by VICI Properties Inc., and pay interest semi-annually starting April 15, 2027
Centerspace completed the sale of 14 multifamily apartment communities and a note receivable, with aggregate gross proceeds of approximately $318.8 million, under a portfolio optimization and deleveraging plan. The company says it expects to use the proceeds to reduce debt and may pay a special distribution of about $50.0 million to $60.0 million to shareholders, though the distribution has not been declared.
Four purchase agreements with three unaffiliated buyers covered 14 communities in Denver, Minnesota, Rapid City, South Dakota, and Bismarck, North Dakota, plus a note receivable.
The Denver, Minnesota, and Rapid City transactions closed in staggered closings in June and July 2026; the Bismarck transaction closed on August 11, 2026.
The company paid $25 million on its unsecured credit facility after the Denver closing and expects to use net proceeds to repay the remaining balance.
The company determined the transactions together constituted a significant disposition of assets; a potential special distribution of $50.0 million to $60.0 million is under evaluation.
Martin Marietta issued $5.5 billion of senior unsecured notes in five series maturing 2029 through 2056, with the proceeds, along with a $1.5 billion term loan, earmarked for the cash purchase of Lhoist North America. The notes carry a special mandatory redemption at 101% of principal if the acquisition is not completed or is abandoned, which adds a repayment risk for shareholders if the deal falls through.
Five series totaling $5.5 billion: $750 million due 2029, $1.25 billion due 2032, $1 billion due 2034, $1.5 billion due 2036 and $1 billion due 2056
Coupons range from 4.850% (2029 notes) to 6.375% (2056 notes)
Proceeds plus a $1.5 billion senior unsecured term loan will pay the cash consideration for the Lhoist North America acquisition
Closing of the offering is expected in the third quarter of 2026, subject to customary conditions
Femasys reported that quarterly sales fell 18.9% to $331,827 in the quarter ended June 30, 2026, mainly due to lower FemVue sales, while the quarterly net loss narrowed slightly to $4.47 million from $4.59 million. The company had about $1.4 million of cash at June 30, 2026, and completed a $30 million private placement after quarter-end, which it says gives it resources for its commercial and clinical plans and restored Nasdaq listing compliance.
Quarterly sales were $331,827, down $77,441 or 18.9% from $409,268 a year earlier; six-month sales rose 0.8% to $756,716.
Quarterly net loss was $4,469,095, or $(1.33) per share, versus $4,585,922, or $(3.18) per share, a year earlier; six-month net loss was $3,622,995 versus $10,482,761.
Cash and cash equivalents were about $1.4 million at June 30, 2026, with a $30 million private placement completed after the quarter, which could bring up to $90 million if warrants are fully exercised.
The company said it regained compliance with Nasdaq Listing Requirements and appointed John Canning as Chief Operating Officer.
PSQ Holdings, Inc. agreed on August 13, 2026 to sell 361,385 shares of Class A common stock at $3.60 per share to a group of its directors and their affiliated entities, raising $1,301,000 in gross proceeds before expenses, and the deal closed the same day. The company plans to use the proceeds for working capital and general corporate purposes, and it agreed to file a registration statement covering the shares with the SEC within 90 days of closing.
Shares sold: 361,385 Class A common shares at $3.60 each, for gross proceeds of $1,301,000 before offering expenses.
Buyers are directors of the company, including Davis Pilot III, Donald J. Trump, Jr., Blake Master, Willie Langston, James Celli and Caitlin Long, or their affiliated entities.
The private placement closed on August 13, 2026, and the shares are not registered under the Securities Act.
The company must file a registration statement within 90 days of closing.
Vuzix entered an Open Market Sales Agreement with Jefferies LLC under which it may sell up to $100,000,000 of common stock from time to time at its discretion. The agreement replaces a prior Jefferies sales agreement from February 9, 2024, under which no sales will be made. Because new shares would be issued into the market, the program could dilute existing shareholders if the company uses it.
Agreement dated August 14, 2026 with Jefferies LLC as sales agent, covering up to $100,000,000 aggregate offering price
Jefferies commission is 3.0% of gross proceeds, plus reimbursement of certain expenses
Sales will be made under an effective Form S-3 (File No. 333-276997) and a prospectus supplement dated August 14, 2026
Replaces the prior Sales Agreement from February 9, 2024; no sales will be made under that prior agreement
Motorsport Games reported second-quarter 2026 revenue of $3.5 million, up 36.6% from a year earlier, and first-half revenue of $7.6 million, up 74.0%. Net income fell to about $0.2 million from $4.2 million, and diluted EPS was $0.08 versus $0.82, because the prior-year quarter included non-recurring gains and development spending nearly tripled.
Q2 2026 revenue was $3.5 million versus $2.6 million in Q2 2025, an increase of 36.6%; six-month revenue was $7.6 million, up 74.0%.
Q2 2026 net income was about $0.2 million versus $4.2 million in Q2 2025; the prior year included $2.3 million in foreign exchange gains and a $0.8 million Wesco Settlement Agreement gain.
Non-GAAP Adjusted diluted EPS was $0.19 in Q2 2026 versus $0.25 a year earlier, and $0.33 for the six months versus $0.24; Q2 Adjusted EBITDA was $0.8 million versus $1.4 million.
Cash and cash equivalents were about $3.9 million at June 30, 2026, and $1.2 million was drawn on a $3 million Citibank revolving line of credit.
Ambow Education Holding reported unaudited results for the six months and three months ended June 30, 2026. First-half net revenues rose 2.0% to $5.2 million, but second-quarter revenue fell 14.3% and the company posted a net loss of $0.1 million, compared with net income of $1.8 million a year earlier, which included a one-time $1.5 million lease settlement gain.
Q2 2026 net revenues fell 14.3% to $2.4 million from $2.8 million, mainly due to lower HybriU licensing and sales.
Q2 2026 gross margin was 50.0%, compared with 53.6% a year earlier, and operating expenses rose 27.3% to $1.4 million.
First-half 2026 net income was $0.3 million, or $0.10 per ADS, versus $1.9 million, or $0.66 per ADS, in the first half of 2025.
Cash resources were $7.2 million as of June 30, 2026, and working capital was positive at $5.5 million.
On August 13, 2026, the NYSE told SES AI that it will start proceedings to delist the company's public warrants and immediately suspend their trading for an abnormally low selling price. The warrants, ticker SES WS, carry a $11.50 exercise price and each is exercisable for one Class A share. Trading in the Class A common stock under SES continues and is unaffected.
NYSE notice received August 13, 2026, under Section 802.01D of the NYSE Listed Company Manual
Warrants (ticker SES WS) trading suspended immediately; delisting requires SEC application and completion of procedures
Each warrant exercisable for one Class A share at $11.50 per share
Class A common stock (SES) continues trading on the NYSE
Zentalis Pharmaceuticals entered an underwriting agreement on August 13, 2026 to sell 23,000,000 new common shares at $3.50 per share, before underwriting discounts. The company estimates net proceeds of about $75.1 million, which it plans to use for clinical trials, regulatory filings, manufacturing, pre-commercial activities and general corporate purposes. Shareholders face dilution from the new shares, and the underwriters also hold a 30-day option to buy up to 3,450,000 more shares.
23,000,000 shares offered at $3.50 per share, less underwriting discounts and commissions
Estimated net proceeds of approximately $75.1 million after discounts and offering expenses
Underwriters have a 30-day option to buy up to 3,450,000 additional shares
Closing expected on August 17, 2026, subject to customary conditions
On August 14, 2026, Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell up to $150.0 million of common stock at its sole discretion. Sales would dilute existing shareholders, and the company says proceeds will fund cytisinicline commercialization, a Phase 3 trial for e-cigarette cessation, and working capital.
Up to $150.0 million of common stock may be sold through Jefferies as sales agent, at the company's discretion
Jefferies may receive compensation of up to 3.0% of aggregate gross proceeds, plus reimbursement of certain expenses
Shares are issued under a Form S-3 registration statement filed January 23, 2026, and a prospectus supplement filed August 14, 2026
The company has no obligation to sell shares and may suspend offers at any time
H&R Block said on August 12, 2026, that directors Robert A. Gerard and Matthew E. Winter will retire and not stand for re-election at the 2026 Annual Meeting in November. The company said their decisions were not due to any disagreement over operations, policies, or practices. Gerard served as Chairman for almost 14 years, and Winter chaired the Compensation Committee.
Robert A. Gerard and Matthew E. Winter notified the Board on August 12, 2026.
Both will remain directors until the 2026 Annual Meeting of Shareholders in November.
Gerard served as Chairman of the Board for almost 14 years; Winter was Chair of the Compensation Committee.
The filing states no disagreement with the company on operations, policies, or practices.
LeonaBio reported a second-quarter 2026 net loss of $19.0 million, or $0.80 per share, up from $7.0 million, or $1.78 per share, a year earlier. The company said higher spending on the Phase 3 ELAINE-3 trial for lasofoxifene drove the increase, and cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, which shareholders may want to track against the company's funding needs.
Net loss was $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared with $7.0 million, or $1.78 per share, a year earlier.
R&D expenses rose to $12.9 million from $3.7 million, driven mainly by clinical trial spend for the ELAINE-3 trial.
Cash, cash equivalents and investments were $51.1 million at June 30, 2026, down from $88.3 million at December 31, 2025; net cash used in operations was $37.9 million for the quarter.
O'Reilly Automotive issued and sold $1.6 billion of senior unsecured notes on August 14, 2026, in three series maturing in 2029, 2031 and 2037. The notes carry fixed rates from 4.800% to 5.550% and rank equally with the company's existing unsecured debt, which is a debt financing rather than a change in operations. The filing does not state how the proceeds will be used.
Issued $700 million of 4.800% notes due August 14, 2029, $500 million of 5.050% notes due August 14, 2031, and $400 million of 5.550% notes due March 14, 2037
Notes are not guaranteed by subsidiaries initially and are effectively junior to any future secured debt
Change of control repurchase price is 101% of principal plus accrued interest; an affiliate of the trustee was an underwriter
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.